Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults
August 20, 2015
In the breast cancer trial, 27 women received the higher dose, of whom 11 responded, while six out of a further 27 women given a lower dose also responded.
Side-effects tended to be relatively mild and included nausea, fatigue and anaemia.
Dr Audeh noted that many women with advanced BRCA-mutated cancer have limited treatment options, as they will have already tried several different chemotherapy drugs.
He revealed: "PARP inhibitors may be a promising new option for this heavily 'pre-treated' population."
Dr Claire Knight, health information officer at Cancer Research UK, said: "PARP inhibitors have been showing excellent promise in early clinical trials and these results are also encouraging.
"Cancer Research UK scientists have been key players in developing this new generation of cancer drugs. We look forward to the results of larger clinical trials to determine if these drugs could be an effective way to treat cancers caused by faults in the BRCA genes."
Source: Cancer Research UK